Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPOWER Study of empagliflozin for chronic euvolemic or hypervolemic hyponatremia
NL-OMON60177Phase 2Completed
- Sponsor
- University Hospital Basel
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hyponatraemia comparing Empagliflozin with Placebo (2 arms). Primary endpoints: Short-term change in average daily plasma sodium AUC and Long-term change in plasma sodium. Started Oct 2025; status: completed.
02
Drugs
empagliflozin
03
Conditions
hyponatraemia
Beyond the preview
Go deeper on NL-OMON60177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60177.